Journal
KIDNEY & BLOOD PRESSURE RESEARCH
Volume 30, Issue 3, Pages 187-194Publisher
KARGER
DOI: 10.1159/000103279
Keywords
adiponectin; hypertension; antihypertensive therapy; insulin resistance; diuretics
Ask authors/readers for more resources
Background/Aim: Adiponectin is an adipose tissue-specific protein with antiatherogenic and insulin-sensitizing properties. In patients with essential hypertension, plasma adiponectin concentrations are lower than in healthy subjects. Antihypertensive drugs do not uniformly influence components of the metabolic syndrome. Therefore, the aim of this study was to evaluate the influence of 6 months' monotherapy with different antihypertensive drugs on plasma adiponectin concentration in essential hypertension patients. Methods: Forty essential hypertension patients were randomized to receive enalapril, metoprolol, amlodipine or indapamide. Plasma concentrations of adiponectin, insulin, glucose and body fat content were estimated twice: before and after 6 months of antihypertensive monotherapy. Results: Plasma adiponectin concentration did not change significantly after enalapril ( 11.5 +/- 4.8 vs. 11.1 +/- 4.1 mg/l), metoprolol ( 10.2 +/- 4.2 vs. 9.8 +/- 4.5 mg/l), and amlodipine ( 9.0 +/- 6.0 vs. 8.5 +/- 5.4 mg/l) treatment. However, a significant decrease of plasma adiponectin concentration ( from 11.6 +/- 4.6 to 10.2 +/- 4.2 mg/l, p = 0.047) was observed in patients treated with indapamide. Additionally in these patients, a significant increase of the HOMA-IR index was found ( p = 0.021). Conclusion: Treatment with indapamide was followed by a significant decrease of plasma adiponectin concentration. This may participate in the pathogenesis of carbohydrate metabolism disturbances often found in patients treated with thiazide-type diuretics. Copyright (c) 2007 S. Karger AG, Basel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available